BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 22123383)

  • 1. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
    Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
    Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial.
    Baş M
    Expert Rev Clin Immunol; 2012 Nov; 8(8):707-17. PubMed ID: 23167682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Icatibant for the treatment of hereditary angioedema.
    Cole SW; Lundquist LM
    Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).
    Bork K; Frank J; Grundt B; Schlattmann P; Nussberger J; Kreuz W
    J Allergy Clin Immunol; 2007 Jun; 119(6):1497-503. PubMed ID: 17418383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
    J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
    Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
    Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
    Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
    Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
    Cicardi M; Banerji A; Bracho F; Malbrán A; Rosenkranz B; Riedl M; Bork K; Lumry W; Aberer W; Bier H; Bas M; Greve J; Hoffmann TK; Farkas H; Reshef A; Ritchie B; Yang W; Grabbe J; Kivity S; Kreuz W; Levy RJ; Luger T; Obtulowicz K; Schmid-Grendelmeier P; Bull C; Sitkauskiene B; Smith WB; Toubi E; Werner S; Anné S; Björkander J; Bouillet L; Cillari E; Hurewitz D; Jacobson KW; Katelaris CH; Maurer M; Merk H; Bernstein JA; Feighery C; Floccard B; Gleich G; Hébert J; Kaatz M; Keith P; Kirkpatrick CH; Langton D; Martin L; Pichler C; Resnick D; Wombolt D; Fernández Romero DS; Zanichelli A; Arcoleo F; Knolle J; Kravec I; Dong L; Zimmermann J; Rosen K; Fan WT
    N Engl J Med; 2010 Aug; 363(6):532-41. PubMed ID: 20818888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.
    Greve J; Hoffmann TK; Schuler P; Lang S; Chaker A; Bas M
    Int J Dermatol; 2011 Oct; 50(10):1294-5. PubMed ID: 21950301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study.
    Zanichelli A; Bova M; Coerezza A; Petraroli A; Triggiani M; Cicardi M
    Allergy; 2012 Aug; 67(8):1074-7. PubMed ID: 22686628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.
    Craig TJ; Levy RJ; Wasserman RL; Bewtra AK; Hurewitz D; Obtułowicz K; Reshef A; Ritchie B; Moldovan D; Shirov T; Grivcheva-Panovska V; Kiessling PC; Keinecke HO; Bernstein JA
    J Allergy Clin Immunol; 2009 Oct; 124(4):801-8. PubMed ID: 19767078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.
    Prescrire Int; 2010 Nov; 19(110):245-7. PubMed ID: 21284353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
    Aberer W; Maurer M; Reshef A; Longhurst H; Kivity S; Bygum A; Caballero T; Bloom B; Nair N; Malbrán A
    Allergy; 2014 Mar; 69(3):305-14. PubMed ID: 24438203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
    Arerugi; 2018; 67(2):139-147. PubMed ID: 29553114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series.
    Bas M; Greve J; Stelter K; Bier H; Stark T; Hoffmann TK; Kojda G
    Ann Emerg Med; 2010 Sep; 56(3):278-82. PubMed ID: 20447725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
    Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
    J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant.
    Krause K; Metz M; Zuberbier T; Maurer M; Magerl M
    J Dtsch Dermatol Ges; 2010 Apr; 8(4):272-4. PubMed ID: 19758369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.
    Longhurst HJ; Aberer W; Bouillet L; Caballero T; Maurer M; Fabien V; Zanichelli A;
    Eur J Emerg Med; 2016 Jun; 23(3):224-7. PubMed ID: 27116379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.